Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A. Kansagra A, et al. Among authors: khouri j. Blood Adv. 2022 Jul 12;6(13):3991-3995. doi: 10.1182/bloodadvances.2022007218. Blood Adv. 2022. PMID: 35507742 Free PMC article. No abstract available.
Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Khouri J, et al. Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938774 Free article. No abstract available.
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Khouri J, Reu F, Majhail NS, Gerds A, Jagadeesh D, Dean R, Sobecks R, Hamilton BK, Pohlman B, Hill BT, Corrigan D, Kalaycio M, Bolwell BJ, Liu HD. Khouri J, et al. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e374-e376. doi: 10.1016/j.clml.2019.03.019. Epub 2019 Apr 8. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31053548 No abstract available.
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Hansen DK, et al. Among authors: khouri j. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623248 Free PMC article.
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: khouri j. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
136 results